Company / Return on Equity (ROE)
ROCKET PHARMACEUTICALS, INC. Return on Equity (ROE) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-55.9%
FY2025
5-year range
-55.9% / -25.1%
FY2021-FY2025
Trend
-24.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
ROCKET PHARMACEUTICALS, INC. reports negative total equity of -55.9% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-55.9% in FY2025 with a 5-year CAGR of -17.5%.
Declined from -37.2% to -55.9% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -28.1pp
- 5-Year Change
- -17.5pp
- 10-Year Change
- -
Key checks
Key Insights
- ROCKET PHARMACEUTICALS, INC.'s return on equity (roe) has declined for 4 consecutive years.
- In FY2025, return on equity (roe) decreased 24.0% year-over-year.
- Peak return on equity (roe) was recorded in FY2021.
- Lowest return on equity (roe) in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.68 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -55.9% | -24.0% |
| FY2024 | -45.0% | -21.1% |
| FY2023 | -37.2% | -34.0% |
| FY2022 | -27.7% | -10.3% |
| FY2021 | -25.1% | +34.5% |
| FY2020 | -38.4% | +92.0% |
| FY2019 | -480.2% | -884.0% |
| FY2018 | -48.8% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026